TruWealth Advisors LLC Grows Stock Position in Johnson & Johnson $JNJ

TruWealth Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,100 shares of the company’s stock after purchasing an additional 77 shares during the period. TruWealth Advisors LLC’s holdings in Johnson & Johnson were worth $779,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. RDA Financial Network increased its stake in shares of Johnson & Johnson by 2.5% in the 2nd quarter. RDA Financial Network now owns 6,059 shares of the company’s stock valued at $926,000 after purchasing an additional 150 shares in the last quarter. Sage Capital Advisors llc increased its stake in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Sage Capital Advisors llc now owns 46,599 shares of the company’s stock valued at $7,118,000 after purchasing an additional 1,650 shares in the last quarter. Fiduciary Financial Group LLC increased its stake in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Fiduciary Financial Group LLC now owns 5,589 shares of the company’s stock valued at $871,000 after purchasing an additional 145 shares in the last quarter. HBW Advisory Services LLC increased its stake in shares of Johnson & Johnson by 10.1% in the 2nd quarter. HBW Advisory Services LLC now owns 8,149 shares of the company’s stock valued at $1,245,000 after purchasing an additional 748 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its stake in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Central Pacific Bank Trust Division now owns 17,357 shares of the company’s stock valued at $2,651,000 after purchasing an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Citigroup boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

Johnson & Johnson Trading Down 0.2%

Shares of Johnson & Johnson stock opened at $178.10 on Friday. The stock has a market cap of $428.93 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40. The stock’s 50 day simple moving average is $170.81 and its 200-day simple moving average is $161.29. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the firm posted $2.82 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.